Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Nanoform Finland Oyj
  6. News
  7. Summary
    NANOFH   FI4000330972

NANOFORM FINLAND OYJ

(NANOFH)
  Report
Delayed Nasdaq Helsinki  -  10:43 2022-09-27 am EDT
3.220 EUR   -0.92%
09/26Nanoform Finland Oyj : unveils new patient statue
PU
09/18Certain Shares of Nanoform Finland Oyj are subject to a Lock-Up Agreement Ending on 18-SEP-2022.
CI
09/07Nanoform Finland Plc - Manager's transactions - Niklas Sandler
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nanoform Finland Plc Partners with Pharmanovia for Iconic Medicines

07/14/2022 | 01:10am EDT

Nanoform Finland plc announced that it has partnered with Pharmanovia. The new strategic partnership aims to add value to branded prescription medicines. Pharmanovia will look to apply Nanoform's proprietary nanoparticle technologies and formulation know-how to leading established pharmaceutical brands.

The partnership starts with an iconic branded medicine where both parties see value in enhancing bioavailability for patient benefit. The value of the stage-gated agreement is according to Nanoform's business model for non-GMP and cGMP work.


© S&P Capital IQ 2022
All news about NANOFORM FINLAND OYJ
09/26Nanoform Finland Oyj : unveils new patient statue
PU
09/18Certain Shares of Nanoform Finland Oyj are subject to a Lock-Up Agreement Ending on 18-..
CI
09/07Nanoform Finland Plc - Manager's transactions - Niklas Sandler
AQ
09/06Share subscriptions based on Nanoform Finland Plc's stock options 2-3/2019 and 1/2020
AQ
08/25Transcript : Nanoform Finland Oyj, H1 2022 Earnings Call, Aug 25, 2022
CI
08/25Nanoform Finland Oyj : Interim Report for January-June 2022
PU
08/25Nanoform Q2 And H1 2022 Report : Strong momentum continues
AQ
08/25Nanoform Finland Oyj Reports Earnings Results for the Second Quarter and Six Months End..
CI
08/10Invitation to Nanoform's Interim Report January-June 2022
AQ
07/14Nanoform and Pharmanovia to breathe new life into iconic medicines
AQ
More news
Financials
Sales 2022 5,00 M 4,80 M 4,80 M
Net income 2022 -22,1 M -21,2 M -21,2 M
Net cash 2022 67,5 M 64,8 M 64,8 M
P/E ratio 2022 -11,1x
Yield 2022 -
Capitalization 252 M 242 M 242 M
EV / Sales 2022 37,0x
EV / Sales 2023 13,2x
Nbr of Employees 143
Free-Float 75,2%
Chart NANOFORM FINLAND OYJ
Duration : Period :
Nanoform Finland Oyj Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANOFORM FINLAND OYJ
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,22 €
Average target price 8,88 €
Spread / Average Target 176%
EPS Revisions
Managers and Directors
Edward Hæggström Chief Executive Officer
Albert Häggström Chief Financial Officer & Director
Miguel Maria de Oliveira Barreiros Calado Chairman
Niklas Sandler Chief Technology Officer
Mads Laustsen Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
NANOFORM FINLAND OYJ-50.61%246
JOHNSON & JOHNSON-3.14%435 655
ELI LILLY AND COMPANY12.76%292 179
ROCHE HOLDING AG-19.31%253 262
ABBVIE INC.4.29%249 673
PFIZER, INC.-25.35%245 989